Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+ T and CAR-T cells.
Jo Y, Shim JA, Jeong JW, Kim H, Lee SM, Jeong J, Kim S, Im SK, Choi D, Lee BH, Kim YH, Kim CD, Kim CH, Hong C.
Jo Y, et al. Among authors: kim yh, kim h, kim cd, kim ch, kim s.
Mol Ther. 2024 Aug 22:S1525-0016(24)00541-0. doi: 10.1016/j.ymthe.2024.08.019. Online ahead of print.
Mol Ther. 2024.
PMID: 39169624
Free article.